Dysbiosis: Recognizing the Hidden Imbalance Driving Modern Chronic Disease

Overview

For decades, biomedical science viewed the human gastrointestinal tract primarily as a terminal digestive conduit. However, contemporary translational research has necessitated a paradigm shift, recasting the human superorganism as a densely integrated supra-organ ecosystem governed by a symbiotic microbial consortium. At the heart of this metabolic axis lies dysbiosis—a pathological disruption of microbial homeostasis characterised by diminished alpha diversity, taxonomic shifts, and functional metabolic aberrations. As documented extensively in peer-reviewed literature indexed in PubMed and synthesised by landmark epidemiological studies published in The Lancet, the chronic modern disease burden sweeping the UK population is inextricably linked to this underlying microbial imbalance. Dysbiosis is no longer regarded merely as an epiphenomenon of ill health; it is increasingly recognised as a primary driver of systemic pathophysiology.

To truly innerstand the cascading systemic consequences of dysbiosis, one must examine the erosion of mutualistic host-microbe interactions at the mucosal interface. In a eubiotic state, commensal taxa—predominantly belonging to the phyla Firmicutes and Bacteroidetes, alongside beneficial Actinobacteria and Verrucomicrobia—ferment non-digestible dietary polysaccharides into short-chain fatty acids (SCFAs), notably butyrate, propionate, and acetate. These microbial metabolites serve as the primary energy substrate for colonocytes, fortify the intestinal epithelial barrier by upregulating tight junction proteins such as zonula occludens-1 (ZO-1) and occludin, and exert profound immunomodulatory effects via the induction of regulatory T cells (Tregs).

Conversely, the hallmark of modern dysbiosis—accelerated by hyper-processed Western diets, ubiquitous xenobiotic exposure, sedentary lifestyles, and the over-prescription of broad-spectrum antimicrobials within the NHS—is the degradation of this protective metabolic architecture. When pathobionts proliferate at the expense of mutualists, the resultant enzymatic profile shifts from saccharolytic to proteolytic fermentation. This metabolic transition yields toxic secondary by-products, including lipopolysaccharides (LPS), trimethylamine (TMA), and p-cresol, which systematically compromise mucosal integrity. The breakdown of the epithelial barrier culminates in metabolic endotoxaemia, a state wherein luminal antigens and pro-inflammatory mediators continuously translocate into the systemic circulation.

This sustained translocation triggers low-grade, chronic systemic inflammation—colloquially termed "metaflammation." Unlike acute inflammatory responses, metaflammation operates subclinically yet persistently, serving as a biochemical catalyst for the pathogenesis of modern non-communicable diseases. As established by extensive gastroenterological and immunological research, this chronic immune activation disrupts insulin signalling pathways, promotes atherogenesis, alters neuroendocrine signalling via the microbiota-gut-brain axis, and deregulates hepatic lipid metabolism. Consequently, dysbiosis underpins the rising incidence of metabolic syndrome, Type 2 diabetes, cardiovascular pathologies, autoimmune disorders, and neurodegenerative conditions across the UK. By decoding the intricate mechanisms of microbial dysbiosis, biomedical research is shifting from downstream symptom management toward targeted, microbiome-centric therapeutic interventions designed to restore systemic homeostasis at its foundational root.

The Biology — How It Works

At the molecular and physiological nexus of modern chronic pathology lies the breakdown of host-microbial symbiosis, a transition state where commensal mutualism degrades into destructive dysbiosis. To comprehend this shift through an evolutionary and mechanistic lens, one must examine the fundamental architectures of the gastrointestinal ecosystem: the single-layered intestinal epithelium and its contiguous, stratified mucus layers, which together interface with an estimated $10^{13}$ to $10^{14}$ microbial organisms. As documented extensively in literature from UK-based cohorts and international consortia (such as the Human Microbiome Project), a healthy eubiotic state is characterized by high taxonomic alpha-diversity, dominated by the phyla Bacteroidetes and Firmicutes, alongside critical minor populations like Akkermansia muciniphila. These organisms do not merely transiently inhabit the lumen; they act as a virtual endocrine organ, metabolically transforming dietary substrates into bioactive postbiotics that dictate systemic homeostasis.

The pathogenesis of dysbiosis begins with a disruption in metabolic output, predominantly the depletion of short-chain fatty acids (SCFAs)—specifically acetate, propionate, and butyrate—produced via the bacterial fermentation of non-digestible dietary carbohydrates (dietary fibre). Butyrate serves as the primary colonocyte energy substrate, upregulating the transcription of genes encoding tight junction proteins such as claudins, occludins, and zonula occludens-1 (ZO-1). When dietary fibre intake plummets—a hallmark of the ultra-processed Western diet prevalent across the UK—SCFA-producing saccharolytic taxa (e.g., Faecalibacterium prausnitzii) atrophy. Concurrently, an overgrowth of pathobionts from the Proteobacteria phylum thrives on host-derived glycans and inflammatory by-products. This compositional shift dismantles the inner mucus layer, as mucin-degrading specialists like Akkermansia over-forage when unsupplied with complex plant polysaccharides, while pathogenic taxa deploy mucinases that breach the structural integrity of the intestinal barrier.

The structural failure of the epithelial barrier precipitates systemic pathophysiological cascades via translocation. As intercellular tight junctions disintegrate due to diminished protein expression and MyD88-dependent inflammatory signalling, luminal antigens, intact lipopolysaccharides (LPS)—the outer membrane endotoxins of Gram-negative bacteria—and unesterified flagellin gain unregulated access to the lamina propria. Here, LPS binds to Toll-like receptor 4 (TLR4) on resident macrophages and dendritic cells, triggering a MyD88-dependent intracellular signalling cascade that culminates in the nuclear translocation of NF-$\kappa$B (Nuclear Factor kappa-light-chain-enhancer of activated B cells). This unleashes a transcriptional storm of pro-inflammatory cytokines, including TNF-$\alpha$, IL-1$\beta$, and IL-6, establishing a state of low-grade, persistent metabolic inflammation colloquially termed "metabolic endotoxemia."

Furthermore, dysbiosis fundamentally skews the host metabolome by subverting the tryptophan, bile acid, and choline metabolic pathways. Symbiotic microbes typically convert dietary tryptophan into indole derivatives that act as ligands for the Aryl Hydrocarbon Receptor (AhR), promoting mucosal immunity and epithelial repair. Dysbiotic microbiomes divert tryptophan down the kynurenine pathway, generating neurotoxic metabolites implicated in central nervous system inflammation and mood disorders. Simultaneously, impaired microbial bile acid deconjugation and 7$\alpha$-dehydroxylation dysregulate farnesoid X receptor (FXR) and G-protein coupled bile acid receptor 1 (TGR5) signalling in the liver and gut, driving hepatic steatosis, dyslipidaemia, and systemic insulin resistance. Through these interwoven, multi-organ pathways—rigorously catalogued in peer-reviewed journals such as The Lancet and Nature—microbial dysbiosis ceases to be an isolated gastroenterological anomaly, instead operating as a primary biological driver of the chronic non-communicable diseases burdening contemporary populations.

Mechanisms at the Cellular Level

To fully comprehend how microbial imbalance cascades into systemic pathology, one must examine the molecular interface between the intestinal lumen and the host mucosal immune apparatus. Dysbiosis is not merely a topographical shift in luminal taxonomy; it represents a fundamental breakdown of homeostatic cross-talk at the cellular level. When the commensal phyla—predominantly Firmicutes and Bacteroidetes—undergo pathological shifts, the downstream metabolic and immunological consequences directly challenge host cellular integrity. This paradigm is a core tenet of the curriculum at INNERSTANDIN, where we dissect the precise biochemical pathways linking microbial metabolites to multi-organ dysfunction.

At the vanguard of this cellular disruption is the compromise of the intestinal epithelial barrier. Under euglycemic and eucaloric conditions, symbiotic bacteria ferment dietary fibre into short-chain fatty acids (SCFAs), primarily butyrate, acetate, and propionate. Butyrate serves as the primary colonocyte bioenergetic substrate, upregulating tight junction proteins such as zonula occludens-1 (ZO-1), occludin, and claudins. Landmark investigations published in The Lancet and indexed across PubMed demonstrate that dysbiosis precipitates a depletion of butyrate-producing taxa, such as Faecalibacterium prausnitzii. Without adequate butyrate, colonocyte mitochondrial $\beta$-oxidation falters, leading to cellular energy starvation, hypoxia-inducible factor (HIF) downregulation, and the subsequent disassembly of the apical junctional complex.

This structural failure initiates a pernicious biochemical cascade. As paracellular permeability increases, luminal antigens, lipopolysaccharides (LPS)—the endotoxins outer-membraned to Gram-negative bacteria—and unesterified flagellins translocate into the lamina propria. Here, LPS binds to the CD14/Toll-like receptor 4 (TLR4) complex on resident macrophages and dendritic cells. This engagement triggers the MyD88-dependent signalling pathway, culminating in the nuclear translocation of nuclear factor kappa B (NF-$\kappa$B) and the massive transcriptional upregulation of pro-inflammatory cytokines, including TNF-$\alpha$, IL-1$\beta$, and IL-6.

Concurrently, the metabolic output of a dysbiotic microbiome shifts from saccharolytic fermentation to proteolytic putrefaction. Undigested dietary proteins reaching the distal gut are metabolized into neurotoxic and vasculotoxic compounds, including p-cresol sulphate, indoxyl sulphate, and trimethylamine (TMA). Hepatic flavin-containing monooxygenases subsequently oxidize TMA into trimethylamine N-oxide (TMAO), a molecule robustly implicated in accelerated endothelial dysfunction, platelet hyper-reactivity, and atherogenesis through the promotion of macrophage scavenger receptors.

Furthermore, dysbiosis disrupts the delicate balance of the enteric neuroendocrine system. Gut microbes modulate the biosynthesis of serotonin (5-hydroxytryptamine) via the up- or down-regulation of tryptophan hydroxylase 1 (TpH1) in enterochromaffin cells, largely driven by microbial-derived secondary bile acids and SCFA signalling. Disruption of this axis impairs enteric peristalsis and visceral hypersensitivity.

Ultimately, cellular-level dysbiosis transcends local mucosal inflammation. By breaching the epithelial fortress, the compromised microbiome orchestrates a systemic, low-grade metabolic inflammation—often termed metabolic endotoxaemia—that underpins modern chronic non-communicable diseases, from insulin resistance to neurodegenerative disorders. Understanding these precise molecular vectors is essential for targeted clinical intervention.

Environmental Threats and Biological Disruptors

The contemporary human gastrointestinal ecosystem is subjected to an unprecedented barrage of xenobiotic and environmental stressors that systematically dismantle ancient host-microbial symbioses. As documented extensively in recent literature from the Lancet and Nature Reviews Gastroenterology & Hepatology, the modern exposome acts as a potent catalyst for intestinal dysbiosis, shifting the luminal landscape from a mutually beneficial metabolic engine to a pro-inflammatory microenvironment. Chief among these disruptors are the ubiquitous presence of ultra-processed foods, chronic low-dose xenobiotic ingestion, and the widespread deployment of broad-spectrum pharmacological agents within Western populations.

Dietary emulsifiers—such as carboxymethylcellulose and polysorbate-80, heavily utilized in industrial food processing across the UK—directly erode the protective colonic mucus layer. Research indexed on PubMed demonstrates that these synthetic detergents reduce the spatial segregation between luminal bacteria and the single-layer intestinal epithelium. By physically breaching this glycan-rich barrier, emulsifiers facilitate direct microbial adhesion and translocation, triggering Toll-like receptor (TLR) signaling cascades and driving chronic, low-grade systemic inflammation. Concurrently, the pervasive infiltration of microplastics and persistent organic pollutants into the food chain alters microbial enzymatic pathways, inducing selective pressures that favour pathobionts over obligate anaerobes like Faecalibacterium prausnitzii.

Pharmacological interventions represent another profound assault on microbial architecture. Beyond the well-established collateral damage inflicted by antibiotics—which drastically deplete species richness and select for antimicrobial-resistance genes—non-antibiotic drugs frequently exert unanticipated antimicrobial activities. Landmark studies published in Nature have revealed that a staggering proportion of common human-targeted therapeutics, including proton-pump inhibitors, non-steroidal anti-inflammatory drugs (NSAIDs), and atypical antipsychotics, inhibit the growth of commensal strains in a manner identical to conventional bactericidal agents. NSAIDs, for instance, compromise mitochondrial respiration in enterocytes and uncouple oxidative phosphorylation, precipitating mucosal ischemia, increased paracellular permeability, and a subsequent cascade of dysbiosis characterized by the proliferation of Enterobacteriaceae.

At INNERSTANDIN, we emphasize that these environmental insults do not operate in isolation; rather, they synergize to dismantle the mucosal immune system's regulatory mechanisms. The resultant ecological collapse is characterized by a loss of short-chain fatty acid (SCFA) producing taxa, precipitating a deficit in luminal butyrate. Because butyrate serves as the primary energy substrate for colonocytes, its absence compromises epithelial hypoxia-inducible factor (HIF) signaling, locking the mucosa into a state of perpetual oxidative stress. This biochemical shift elevates luminal oxygen tensions, oxidizing anaerobic niches and further accelerating the eradication of health-promoting taxa. Understanding these multi-factorial vectors of disruption is paramount for clinicians and researchers attempting to reverse the rising tide of chronic non-communicable diseases rooted in microbial dysregulation.

The Cascade: From Exposure to Disease

The transition from localized microbial perturbation to systemic pathology represents one of the most rigorously mapped pathophysiological cascades in contemporary molecular medicine. As documented extensively in peer-reviewed literature indexed on PubMed, the disruption of the intestinal architecture does not remain confined to the luminal interface; rather, it initiates a multi-organ cascade driven by biochemical signaling, metabolic diversion, and immunological subversion. When persistent dysbiosis degrades the protective mucous layer and compromises the intercellular tight junctions—predominantly composed of claudins, occludins, and zonula occludens-1 (ZO-1) proteins—the physiological barrier function fails. This breakdown permits the translocation of immunogenic microbial-associated molecular patterns (MAMPs), most notably lipopolysaccharides (LPS) from Gram-negative bacterial outer membranes, directly into the mesenteric circulation.

Once systemic, circulating LPS binds to Toll-like receptor 4 (TLR4) complexes on resident macrophages, dendritic cells, and endothelial linings, triggering a signaling cascade via the MyD88-dependent pathway. This activates nuclear factor kappa-light-chain-enhancer of activated B cells (NF-$\kappa$B), culminating in the robust transcription and systemic release of pro-inflammatory cytokines, including Tumor Necrosis Factor-alpha (TNF-$\alpha$), Interleukin-1 beta (IL-1$\beta$), and Interleukin-6 (IL-6). At INNERSTANDIN, our anatomical analyses emphasize that this low-grade, chronic systemic inflammation is not a transient acute-phase response, but a persistent immunological hum that fundamentally alters metabolic homeostasis. The resulting cytokine milieu directly interferes with insulin receptor substrate-1 (IRS-1) phosphorylation, inducing peripheral insulin resistance—a foundational mechanism in the pathogenesis of metabolic syndrome and type 2 diabetes.

Simultaneously, the metabolic output of the dysbiotic microbiome undergoes a pathogenic shift. A depletion of saccharolytic taxa (such as Faecalibacterium prausnitzii and Roseburia intestinalis) results in a critical deficit of short-chain fatty acids (SCFAs), particularly butyrate, acetate, and propionate. Butyrate serves as the primary colonocytic energy substrate and an endogenous histone deacetylase (HDAC) inhibitor, vital for maintaining regulatory T cell ($T_{reg}$) homeostasis and mucosal immune tolerance. In its absence, mucosal immunity skews toward a Th1/Th17 inflammatory phenotype. Furthermore, alterations in proteolytic fermentation produce aberrant metabolic byproducts, including trimethylamine (TMA). As demonstrated in landmark studies published in The Lancet and related cardiovascular journals, host hepatic flavin-containing monooxygenases oxidize gut-derived TMA into trimethylamine N-oxide (TMAO), a pro-atherogenic molecule that accelerates endothelial injury, foam cell formation, and plaque destabilisation.

This biochemical domino effect extends inexorably to the central nervous system via the bidirectional vagus nerve and neuro-endocrine pathways. Circulating pro-inflammatory cytokines compromise the blood-brain barrier (BBB), activating microglial cells and inducing neuroinflammation. Concurrently, dysbiosis disrupts the microbial synthesis of neurotransmitters and their precursors, including serotonin, gamma-aminobutyric acid (GABA), and dopamine. This disruption explains the high comorbidity of chronic neurodegenerative and psychiatric phenotypes observed in UK population cohorts. Ultimately, understanding this cascade transforms our approach to chronic disease: what manifests as isolated pathologies across cardiology, endocrinology, and neurology often traces its etiology back to the molecular disintegration of the gut ecosystem.

What the Mainstream Narrative Omits

For decades, mainstream clinical gastroenterology has reduced dysbiosis to a superficial paradigm: an overgrowth of pathobionts countered by standard probiotic supplementation or broad-spectrum antimicrobial eradication. This reductionist framework fundamentally misinterprets the complexity of the human gastrointestinal ecosystem. As established by landmark profiling initiatives such as the Human Microbiome Project and subsequent longitudinal cohorts published in Nature and The Lancet, dysbiosis is rarely an isolated taxonomic imbalance. Rather, it represents a profound metabolic, architectural, and immunological collapse of the mucosal-microbial interface.

Conventional diagnostics rely heavily on stool-based shotgun metagenomics or 16S rRNA sequencing that capture luminal planktonic populations while entirely omitting the mucosa-adherent microbiota. This methodological blind spot ignores the biofilm architectures residing within the crypts of Lieberkühn. Within these structured communities, microorganisms coordinate metabolic cross-feeding and horizontal gene transfer away from the fecal stream. Consequently, standard clinical interventions target planktonic anomalies while leaving mucosa-invasive pathobionts—such as adherent-invasive Escherichia coli (AIEC) strains heavily implicated in chronic inflammatory bowel pathologies—untouched.

Furthermore, the mainstream narrative routinely overlooks the critical erosion of the gut's metabolic output. Dysbiosis is fundamentally a state of functional starvation for the host epithelium. When saccharolytic taxa decline due to low-fibre diets prevalent in the UK—where over 90% of the population fails to meet the Scientific Advisory Committee on Nutrition (SACN) 30g daily fibre threshold—the production of vital short-chain fatty acids (SCFAs) like butyrate plummets. Standard medical management treats downstream systemic autoimmunity, metabolic syndrome, and neuroinflammation as discrete, idiopathic failures. It fails to interrogate the upstream loss of microbial tryptophan metabolites and secondary bile acids that act as indispensable ligands for the aryl hydrocarbon receptor (AhR) and farnesoid X receptor (FXR). These pathways are master regulators of systemic immune homeostasis and intestinal barrier integrity.

At INNERSTANDIN, we recognise that restoring systemic health requires dismantling this outdated dogma. True therapeutic resolution demands shifting focus from mere taxonomic headcounts to rigorous functional metabolomics, restoring mucosal niche specialisation, and repairing the biophysical integrity of the gut barrier before chronic systemic sequelae become irreversible.

The UK Context

Within the United Kingdom, the escalation of non-communicable chronic diseases presents an acute public health crisis that increasingly intersects with foundational perturbations of the gastrointestinal ecosystem. Epidemiological data from bodies such as the Office for National Statistics and extensive cohort studies, including the TwinsUK registry, demonstrate a striking correlation between the Westernised British diet—characterised by high consumption of ultra-processed foods (UPFs), refined sugars, and xenobiotic additives—and a profound collapse in intestinal microbial alpha-diversity. As documented in landmark analyses published in The Lancet and Nature, this nutritional paradigm starves obligate saccharolytic commensals, specifically the phylum Bacteroidetes and genera such as Faecalibacterium prausnitzii, which are critical for the fermentation of dietary fibre into short-chain fatty acids (SCFAs) like butyrate, propionate, and acetate.

The consequent functional dysbiosis initiates a cascading breakdown of host-microbe homeostasis. Without adequate butyrate concentrations to fuel colonocytes, the integrity of the tight junction proteins—namely occludin, claudin-1, and zonula occludens-1 (ZO-1)—deteriorates. This compromised mucosal barrier permits the paracellular translocation of luminal lipopolysaccharides (LPS) from Gram-negative bacteria into the portal circulation, establishing a state of metabolic endotoxaemia. At INNERSTANDIN, our synthesis of recent PubMed-indexed immunology literature highlights how circulating LPS binds to Toll-like receptor 4 (TLR4) on hepatic, adipose, and endothelial cells, persistently activating nuclear factor kappa B (NF-$\kappa$B) pathways. This molecular cascade drives systemic low-grade inflammation, providing a mechanistic bridge linking UK-centric rises in autoimmune pathologies, metabolic syndrome, neurodegenerative decline, and treatment-resistant depressive disorders directly to the loss of commensal resilience within the British gut microbiome.

Protective Measures and Recovery Protocols

Therapeutic reversal of intestinal dysbiosis requires transitioning from palliative symptom management to targeted ecological restoration of the gastrointestinal mucosa. As established in landmark longitudinal studies published in The Lancet, dysbiosis-driven chronic pathology is perpetuated by a self-reinforcing loop of mucosal barrier degradation, aberrant toll-like receptor (TLR) signalling, and low-grade systemic inflammation. At INNERSTANDIN, our synthesis of contemporary UK clinical immunology and microbial genomics dictates that effective recovery protocols must bypass broad-spectrum interventions in favour of precision manipulation of the gut ecosystem. Restoring eubiosis demands a sequential, biologically stratified framework: elimination of pathological stressors, targeted metabolic supplementation, and reinforcement of the host-microbe interface.

The foundational phase mandates the strategic attenuation of pathobiont populations without triggering collateral devastation of commensal taxa. While conventional clinical practice historically relied on indiscriminate antimicrobials, emerging PubMed-indexed trials highlight the efficacy of precision phytotherapeutics—such as berberine, oregano-derived carvacrol, and allicin—which selectively inhibit proteolytic, pro-inflammatory species (e.g., Proteobacteria) while preserving essential saccharolytic fermenters like Faecalibacterium prausnitzii. Concurrently, mitigation of dietary antigens and emulsifiers (such as carboxymethylcellulose and polysorbate-80, heavily scrutinized in British toxicological reviews) is non-negotiable to halt detergent-mediated disruption of the inner mucus layer.

Following microbial clearance, the intervention must pivot toward metabolic substrate repletion. The administration of precisely engineered prebiotic oligosaccharides—specifically short-chain fructooligosaccharides (FOS) and galactooligosaccharides (GOS)—serves to cross-feed depleted keystone taxa. This metabolic stimulation upregulates the synthesis of short-chain fatty acids (SCFAs), predominantly butyrate, acetate, and propionate. Butyrate acts as the primary mitochondrial respiratory fuel for colonocytes, directly upregulating the transcription of tight-junction proteins, including zonula occludens-1 (ZO-1) and occludin. By reinforcing apical junctional complexes, SCFAs effectively seal the paracellular space, thereby terminating the leakage of lipopolysaccharides (LPS) into the portal circulation and arresting metabolic endotoxemia.

Furthermore, mucosal restoration necessitates direct nutritional scaffolding for enterocyte regeneration and immune modulation. L-glutamine administration provides the primary nitrogenous fuel source for rapidly proliferating enterocytes, accelerating villous repair. Concurrently, the integration of targeted multi-strain psychobiotic and immunobiotic formulations—particularly strains exhibiting robust epithelial adherence profiles, such as Bifidobacterium infantis 35624 and Lactobacillus rhamnosus GG—facilitates competitive exclusion of opportunistic pathogens and modulates mucosal secretory IgA (sIgA) output. Ultimately, overcoming chronic dysbiosis is not merely about introducing transient transient flora; it is an exercise in ecological engineering, re-establishing the homeostatic crosstalk between the host genome and the metagenomic microbial organ to sustainably resolve systemic disease pathways.

Summary: Key Takeaways

Emerging data indexed across PubMed and The Lancet underscores that intestinal dysbiosis is no longer viewed merely as a localized gastroenterological aberration, but as a primary systemic driver of modern chronic pathology. As rigorously mapped within our biological education modules at INNERSTANDIN, the collapse of microbial diversity—characterized by the depletion of anti-inflammatory butyrate-producing taxa such as Faecalibacterium prausnitzii and the concomitant expansion of pathobionts—directly compromises the integrity of the intestinal epithelial barrier. This breakdown precipitates zonulin-mediated tight junction disassembly, driving translocation of lipopolysaccharides (LPS) into the systemic circulation. The resultant metabolic endotoxaemia activates Toll-like receptor 4 (TLR4) pathways, sustaining a state of low-grade, chronic systemic inflammation. As demonstrated by UK-based microbiome cohorts, this molecular cascade underpins insulin resistance, neuroinflammation via the vagus nerve-mediated gut-brain axis, and epigenetic dysregulation. Reversing these pathologies requires an evidence-led paradigm shift: transitioning from symptomatic management to targeted, mechanistic restoration of host-microbial symbiosis.